Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised…
By Y. Bang, E. Van Cutsem, A. Feyereislova, H. Chung, L. Shen, A. Sawaki, F. Lordick, A. Ohtsu, Y. Omuro, T. Satoh and 6 more. The Lancet, 2010
6,747 citations recorded by the source corpus.
BACKGROUND Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2; also known as ERBB2), was investigated in combination with chemotherapy for first-line treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer. METHODS ToGA (Trastuzumab for Gastric Cancer) was an open-label, international, phase 3, randomised controlled trial undertaken in 122 centres in 24 countries. Patients with gastric or gastro-oesophageal junction cancer were eligible for inclusion if their tumours showed overexpression of HER2 protein by immunohistochemistry or gene amplification by fluorescence in-situ hybridisation. Participants were randomly assigned in a 1:1 ratio to receive a chemotherapy regimen consisting of capecitabine plus cisplatin or fluorouracil plus cisplatin given every 3 weeks for six cycles or chemotherapy in combination with intravenous trastuzumab. Allocation was by block randomisation stratified by Eastern Cooperative Oncology Group performance status, chemotherapy regimen, extent of disease, primary cancer site, and measurability of disease, implemented with a central interactive voice recognition system. The primary endpoint was overall survival in all randomised patients who received study medication at least once. This trial is registered with ClinicalTrials.gov, number NCT01041404. FINDINGS 594 patients were randomly assigned to study treatment (trastuzumab plus chemotherapy, n=298; chemotherapy alone, n=296), of whom 584 were included in the primary analysis (n=294; n=290). Median follow-up was 18.6 months (IQR 11-25) in the trastuzumab plus chemotherapy group and 17.1 months (9-25) in the chemotherapy alone group. Median overall survival was 13.8 months (95% CI 12-16) in those assigned to trastuzumab plus chemotherapy compared with 11.1 months (10-13) in those assigned to chemotherapy alone (hazard ratio 0.74; 95% CI 0.60-0.91; p=0.0046). The most common adverse events in both groups were nausea (trastuzumab plus chemotherapy, 197 [67%] vs chemotherapy alone, 184 [63%]), vomiting (147 [50%] vs 134 [46%]), and neutropenia (157 [53%] vs 165 [57%]). Rates of overall grade 3 or 4 adverse events (201 [68%] vs 198 [68%]) and cardiac adverse events (17 [6%] vs 18 [6%]) did not differ between groups. INTERPRETATION Trastuzumab in combination with chemotherapy can be considered as a new standard option for patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer. FUNDING F Hoffmann-La Roche.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/198679eee53032443122b876740e707d56a3a645
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
- J. Reis-Filho
- Allison O'Hair
- J. Baselga
- J. Seoane
- Japanese Gastric Cancer Association
- Dimitris J. Bertsimas
- William C. Hahn
- Gad Getz
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition) (2022, methodology): “The definition of HER2-positive in the ToGA trial was either IHC3 + or FISH-positive [50].”
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO Precision Medicine Working Group. (2020, background): “In these patients, trastuzumab demonstrated a significant improvement of OS in randomised trials.(103) According to basket trials, patients with MSI-H and NTRK fusion-positive tumours treated with ICIs and TRK inhibitors are expected to provide benefit.”
- An Analytics Approach to Designing Combination Chemotherapy Regimens for Cancer (2016, background): “…studies, including cancer extent, histology, a patient’s history of prior adjuvant therapy and surgery, and further details of patients’ initial conditions, such as their baseline bilirubin levels or body surface areas (Ajani et al. 2010, Bang et al. 2010, Kang et al. 2009, Koizumi et al. 2008).”
- Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets (2015, background): “Although HER2amplifications are not commonly observed in serous ovarian cancer (29), such amplification events have been shown to confer sensitivity to anti-HER2 therapy in breast and other cancers (30).”
- Tumor Targeting via EPR: Strategies to Enhance Patient Responses (2018, background): “The antibody blocks the HER2 receptor, which is overexpressed in around 30% of breast cancer patients [166], and also around 20% of gastric cancer patients [167].”